Therefore, almost all scientific guidelines now recommend specific treatments for patients with type 2 diabetes based on CVOTs data, namely adding to metformin a SGLT-2 inhibitor or a GLP-1RA with proven CV disease benefit in patients with type 2 diabetes and CV disease, established kidney disease, or HF [7,8,9,10]
Our dedicated team is here to support you every step of the way, providing guidance and resources to optimize your weight loss outcomes and overall wellness
The EMPA-KIDNEY Collaborative Group
GLP-1 microdosing is generally well-tolerated and associated with fewer side effects compared to higher-dose therapy
GLP-1 therapies are shaking up the world of diabetes and obesity care, opening new doors for both patients and pharmaceutical companies